Autor:innen:
L. Garcia-Pérez (Alcobendas, ES)
H. Sapin (Neuilly Sur Seine, FR)
K. Norrbacka (Helsinki, FI)
B. Guerci (CHRU de Nancy, FR)
F. Giorgino (Aldo Moro, IT)
U. Aigner (Sulzbach-Rosenberg, DE)
M. Orsini Federici (Florence, IT)
R. Gentilella (Florence, IT)
E. Heitmann (Bad Homburg, DE)
H. Jung (Bad Homburg, DE)
M. Rosilio (Neuilly Sur Seine, FR)
K. Boye (Indianapolis, US)
Objective: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are usually recommended as first injectable therapy for type 2 diabetes (T2D). Randomized clinical trials are standard for assessing efficacy and safety, observational studies are valuable to understand GLP-1RA use in clinical practice. Methods: TROPHIES is a 24-month, prospective, observational study in France, Germany, Italy in adult patients with T2D initiating first injectable glucose-lowering treatment with once-weekly dulaglutide/once-daily liraglutide. The primary outcome, time on first GLP-1RA without significant treatment change due to T2D-related factors, was defined as discontinuation of this GLP-1RA/intensification of glucose-lowering treatment. At baseline, demographics, T2D duration, HbA1c levels, reported HbA1c targets, pre-existing diabetes-related diagnoses and concomitantly used oral glucose-lowering medications were assessed. Results: To date, data from 2065 patients initiating dulaglutide (1089) or liraglutide (976) are analyzed. For patients initiating dulaglutide or liraglutide, mean age 58.9 and 59.4yr, 55.3% and 57.4% were male, with mean duration of T2D 8.7 and 8.3yr, and mean BMI 33.8 and 34.1kg/m2, respectively. Mean baseline HbA1c level 8.2% (dulaglutide) and 8.3% (liraglutide) exceeded reported mean HbA1c target 6.9%. Macrovascular and microvascular diabetes related conditions were reported in 8.2% and 17.7% (dulaglutide) and 11.5% and 15.5% (liraglutide) patients, respectively. Of patients initiating dulaglutide or liraglutide, 27.5% and 25.5% had taken ≥2 concomitant oral glucose-lowering medications, respectively, biguanides being most common. Conclusion: In both groups, BMI reflected obesity. HbA1c levels exceeded reported targets justifying treatment intensification with GLP-1RA after ~8.5yr of diabetes. This study helps understand profiles of patients being prescribed dulaglutide or liraglutide in France, Germany, Italy.